Intelligence Feed event · Equity · 2026-09-21

    Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix

    Question

    Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix

    Direct answer

    Bristol Myers Squibb reported Q2 revenue of $12.9 billion alongside a 153% surge in adjusted EPS. The performance was anchored by its growth portfolio of commercial assets, which expanded 15% year-over-year. The growth portfolio now represents nearly 60% of aggregate revenue, blunting the revenue erosion from mature legacy products facing patent expirations. Despite a 17% year-to-date share price gain, BMY continues to trade at a valuation discount against diversified large-cap pharmaceutical peers.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/bristol-myers-squibb-posts-12-9b-revenue-as-new-therapies-reach-60-of-mix-e06a43

    EQUITY
    Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix
    Bristol Myers Squibb reported Q2 revenue of $12.9 billion alongside a 153% surge in adjusted EPS. The performance was anchored by its growth portfolio of commercial assets, which expanded 15% year-over-year. The growth portfolio now represents nearly 60% of aggregate revenue, blunting the revenue erosion from mature legacy products facing patent expirations. Despite a 17% year-to-date share price gain, BMY continues to trade at a valuation discount against diversified large-cap pharmaceutical peers.
    BMYXLV
    Impact
    73
    SEP 21
    SIG
    88%
    BMYXLV
    Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix
    Bristol Myers Squibb reported Q2 revenue of $12.9 billion alongside a 153% surge in adjusted EPS. The performance was anchored by its growth portfolio of commercial assets, which expanded 15% year-over-year. The growth portfolio now represents nearly 60% of aggregate revenue, blunting the revenue erosion from mature legacy products facing patent expirations. Despite a 17% year-to-date share price gain, BMY continues to trade at a valuation discount against diversified large-cap pharmaceutical peers.
    → Accelerating revenue mix transition into non-patent-cliff commercial assets lifts BMY operating cash flow predictability and expands forward P/E multiples relative to the XLV benchmark.
    Impact
    Bristol Myers Squibb reported Q2 revenue of $12.9 billion alongside a 153% surge in adjusted EPS. The performance was anchored by its growth portfolio of commercial assets, which expanded 15% year-over-year. The growth portfolio now represents nearly 60% of aggregate revenue, blunting the revenue erosion from mature legacy products facing patent expirations. Despite a 17% year-to-date share price gain, BMY continues to trade at a valuation discount against diversified large-cap pharmaceutical peers.
    Affected
    BMYXLV
    Transmission
    Accelerating revenue mix transition into non-patent-cliff commercial assets lifts BMY operating cash flow predictability and expands forward P/E multiples relative to the XLV benchmark.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BMYpatent-cliff mitigation supporting forward cash flow multiplesUp1-4wBMY Q2 revenue reached $12.9B with growth portfolio reaching ~60% of total revenue.
    XLVlarge-cap biopharma earnings contributionUp1-4wBMY constitutes a top-ten constituent in broad US healthcare benchmarks.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XLVUpagreed169.01 2026-09-21+0.52%+1.33%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month